heart failure glp 1 GLP-1RAs reduce cardiovascular deaths in patients with CKM comorbidity | Duke Clinical Research Institute posted on the topic GLP-1 Agonists in Cardiovascular Diseases:

Results from a 20-week phase 1b clinical trial showed that a once-weekly dose of 2.4 mg cagrilintide in combination with an equal dose of semaglutide, collectively termed cagrisema, achieved up to 17.1% weight reduction in the obese population

FDA.gov (accessed 26 July 2025)

Injection appointments only take a few minutes, and injections from our highly trained registered nurses are relatively painless

Eur J Neurosci 57(1):148162 Daniele G, Iozzo P, Molina-Carrion M et al (2015) Exenatide regulates cerebral glucose metabolism in brain areas associated with glucose homeostasis and reward system

These are given twice a week or thrice a week, or once a month